Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1583186 | 0.98 | SLC6A2 (0.38) | CHRNA7SLC6A2SLC6A4SLC6A3PARP1 | |
| SCHEMBL8496732 | 0.77 | CHRNA7 (0.42) | CHRNA7SLC6A2CACNA2D1PDE4APDE4B | |
| SCHEMBL5605046 | 0.74 | HPGD (0.46) | CHRNA7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3668110 | 0.72 | HPGD (0.42) | CHRNA7CACNA2D1PDE4APDE4BPDE4C | |
| SCHEMBL1583939 | 0.72 | DRD2 (0.39) | SLC6A2SLC6A4SLC6A3PARP1PIM1 | |
| SCHEMBL598888 | 0.72 | ADRB1 (0.39) | SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL532873 | 0.72 | NPC1 (0.50) | SLC6A2SLC6A4SLC6A3MEN1MAPT | |
| Hydrochloric Acid SCHEMBL1583951 | 0.71 | DRD2 (0.39) | SLC6A2SLC6A4SLC6A3PARP1KMT2A | |
| SCHEMBL4328483 | 0.71 | ADRB1 (0.47) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2854834 | 0.70 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1534292-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1578429-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1511745-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7109233-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1532115-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050256105-A1 | Cysteine protease and serine protease inhibitors; arthritis, parasite infections, osteoporosis, gingivitis; e.g. benzofuran-2-carboxylic acid [(S)-1-((S)-1-cyclohexylmethyl-3,7-dioxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide | JEONG JAE U | 2005-11-17 | — | — | US | disclosed |
| US-20050256100-A1 | Protease inhibitors | JEONG JAE U | 2005-11-17 | — | — | US | disclosed |
| WO-2003103574-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104257-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003099844-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003097593-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| CN-1416346-A | Peotease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | CN | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0342536-B1 | THIENYL-PIPERAZINONES, THEIR PREPARATION AND USE | CASSELLA Aktiengesellschaft (DE) | 1992-09-23 | — | — | EP | disclosed |
| US-4898866-A | NOOTROPIC AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1990-02-06 | — | — | US | disclosed |
| EP-0342536-A1 | Thienyl-piperazinones, their preparation and use | CASSELLA Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CHRNA7 4602/4885SLC6A2 4681/4885SLC6A4 3780/4885 |
| US-20050256100-A1 | Protease inhibitors | SPINT2, PRSS1, ADAM17 | CHRNA7 4844/4885SLC6A2 4706/4885SLC6A4 4156/4885 |
| US-20050256105-A1 | Cysteine protease and serine protease inhibitors; arthritis, parasite infections, osteoporosis, gingivitis; e.g. benzofuran-2-carboxylic acid [(S)-1-((S)-1-cyclohexylmethyl-3,7-dioxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide | PRSS1, SPINT2, CTRL | CHRNA7 4230/4885SLC6A2 4829/4885SLC6A4 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.